An examination of educational gaps in the diagnosis and treatment of myelodysplastic syndromes

Cancer Control

Volumn 18, Issue 1, 2011, Pages 65-74

  Shammo, Jamile M ^a   Foran, James M ^b   Houk, Alice ^c   Epstein, James ^d   Narang, Mohit ^e   Rubinstein, Pesha ^f   Dennison, Betsy ^g   Latsko, Joan M ^h   Naganna, Gourishankar ⁱ  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Aplastic Anemia and MDS International Foundation   (United States)

^d LLC   (United States)

^e MD   (United States)

^f Education Outcomes Science   (United States)

^g OPTUM   (United States)

^h WESTERN PENNSYLVANIA HOSPITAL   (United States)

ⁱ Carroll Hospital Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AWARENESS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; EDUCATION PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFORMATION DISSEMINATION; MEDICAL EDUCATION; MYELODYSPLASTIC SYNDROME; PATIENT ASSESSMENT; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT MONITORING; PATIENT REFERRAL; RISK ASSESSMENT;

EID: 78651472286     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800110     Document Type: Article

References (37)

1. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. V2.0, 2010. http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp. Accessed September 17, 2010.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088. Erratum in: Blood. 1998;91(3):1100.
3. Mufti GJ, Bettett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.
4. Surveillance, Epidemiology and End Results (SEER). Myelodysplastic Syndromes Cancer Statistics Review. http://seer.cancer.gov/csr/1975_ 2006/results_merged/sect_30_mds.pdf. Accessed September 17, 2010.
5. Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-1542.
6. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004;104(8):2263-2268.
7. Sekeres MA, Maciejweski JP, List AF, et al. Perceptions of disease state, treatment expectations, and prognosis among patients with myelodysplastic syndromes. Blood. 2009;114:1771. Abstract.
8. Steensma DP. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006;30(10): 1227-1233.
9. SEER Cancer Statistics Review 1975-2006. Section 30. Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic, Myelomonocytic Leukemia (CMML). http://seer.cancer.gov/ csr/1975_2006/results_merged/sect_30_mds.pdf. Accessed September 22, 2010.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7): 2292-2302.
11. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
12. Delbecq AL, Van de Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci. 1971;7:466-492.
13. Myelodysplastic Syndromes: Creating Awareness in the Primary Care Setting. Presented at the California Academy of Family Practice 61st Annual Scientific Assembly. April 18-19, 2009. San Francisco, CA.
14. Challenging Cases in Hematology. NMCR Challenging Cases Market Research Event Series. July 8, 2009. Miami, FL.
15. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005;353 (5):498-507.
16. MDS Foundation. Virtual Microscopy. http://www.mds-foundation. org/virtualmicroscopy/home.html. Accessed April 26, 2010.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451-458.
18. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
19. Chun K, Hagemeijer A, Iqbal A, et al. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: an International Working Group on MDS Cytogenetics Study. Leuk Res. 2010;34(2):160-165.
20. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
21. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915.
22. Sanz G, Nomdedeu B, Such E, et al. Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. Blood. 2008;112:640. Abstract.
23. Phase III MDS Clinical Trials and Survival. http://www.clinicaltrials. gov/ct2/results?term=MDS+AND+Survival+AND+Phase+III. Accessed September 22, 2010.
24. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
25. List AF. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control. 2008;15(suppl):29-39.
26. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
27. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27(23):3842-3848.
28. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109-2117.
29. Sekeres MA, List AF. Active treatment strategies improving outcomes in patients with myelodysplastic syndromes with the del(5q) abnormality. Clinical Leukemia. 2008;2:28-33.
30. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-3903.
31. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
32. Best of ASCO Annual Meeting '10. http://boa2010.asco.org. Accessed September 22, 2010.
33. MedscapeCME Oncology Insights. http://cme.medscape.com/view program/14793. Accessed October 8, 2010.
34. Highlights from ASCO Annual Meetings: Clinical trial results from the American Society of Clinical Oncology (ASCO). http://www.cancer.gov/ clinicaltrials/results/ASCO-highlights. Accessed September 22, 2010.
35. Highlights of ASH®. The Only Official Highlights of ASH®. http://www. hematology.org/meetings/highlights/. Accessed September 22, 2010.
36. UpToDate®. http://www.uptodate.com/home/index.html. Accessed September 22, 2010.
37. CLINICAL CARE OPTIONS® ONCOLOGY. http://www.clinicaloptions. com/Oncology.aspx. Accessed September 22, 2010.